ORIGINAL PAPER
Long-term observation of ocular toxoplasmosis in immunocompetent children
 
More details
Hide details
 
Publication date: 2018-03-19
 
 
Pediatr Pol 2018;93(1):17-22
 
KEYWORDS
ABSTRACT
Introduction:
Toxoplasma gondii infection may result in retinochoroiditis and vision impairment.

Aim of the study:
We conducted a long-term observation of symptoms and titres of serum anti-Toxoplasma IgG in children and adolescents. Thirty-four children (23 girls and 11 boys), aged one week to 18 years (mean 7.3 ±5.5 years) were observed for 2 to 17 years (mean 5.1 ±3.4 years). Diagnosis was based on detection of characteristic lesions in fundoscopy and positive serum anti-Toxoplasma IgG titres, and inflammation was confirmed by the leakage of dye in fluorescein angiography.

Results:
In seven children the lesions were present at birth; they were bilateral and larger than 1 DD, in six of them they were accompanied by central nervous system abnormalities, and two children presented strabismus. Central localisation of toxoplasmosis, causing vision impairment, and inflammation recurrence, were found with similar frequency in these seven as in the other 27 children. Serum anti-T. gondii IgG ranged from 13 U/l to 1170 U/l, and titres were significantly higher in acute inflammation than in remission: 178 U/l vs. 90 U/l, p = 0.0016. Recurrences (one to three episodes) were noticed in 22/34 children: in all seven and in 15 out of 27 other children.

Conclusions:
Ocular lesions in toxoplasmosis that initiated in foetal life were diffuse and led to progressive impairment of vision in childhood. Recurrence may be expected in more than half of all ocular toxoplasmosis cases despite antiparasitic treatment. Increase of serum anti-Toxoplasma IgG titre may indicate recurrence of retinochoroiditis.
REFERENCES (34)
1.
Kaye A. Toxoplasmosis: diagnosis, treatment, and prevention in congenitally exposed infants. J Pediatr Health Care 2011; 25: 355-364.
 
2.
Hampton MM. Congenital toxoplasmosis: a review. Neonatal Netw 2015; 34: 274-278.
 
3.
Guha R, Miley L, Aspiri M i wsp. Congenital toxoplasmosis. Pediatr Neurol 2017; 70: 81-82.
 
4.
Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol 2004; 137: 1-17.
 
5.
Dard C, Chemla C, Fricker-Hidalgo H i wsp. Late diagnosis of congenital toxoplasmosis based on serological follow-up: a case report. Parasitol Int 2017; 66: 186-189.
 
6.
Brydak-Godowska J, Moneta-Wielgoś J, Kęcik D i wsp. Management of toxoplasmic retinochoroiditis during pregnancy, postpartum period and lactation: clinical observations. Med Sci Monit 2015; 21: 598-603.
 
7.
Brydak-Godowska J, Borkowski PK, Rabczenko D i wsp. Do pregnancy, postpartum period and lactation predispose to recurrent toxoplasmic retinochoroiditis? Med Sci Monit 2015; 21: 582-584.
 
8.
Ongkosuwito JV, Bosch-Driessen EH, Kijlstra A, i wsp. Serologic evaluation of patients with primary and recurrent ocular toxoplasmosis for evidence of recent infection. Am J Ophthalmol 1999; 128: 407-412.
 
9.
Novais EA, Commodaro AG, Santos F i wsp. Patients with diffuse uveitis and inactive toxoplasmic retinitis lesions test PCR positive for Toxoplasma gondii in their vitreous and blood. Br J Ophthalmol 2014; 98: 937-940.
 
10.
Santos FF, Nascimento H, Muccioli C i wsp. Detection of Toxoplasma gondii DNA in peripheral blood and aqueous humor of patients with toxoplasmic active focal necrotizing retinochoroiditis using real-time PCR. Arq Bras Oftalmol 2015; 78: 356-358.
 
11.
Butler NJ, Furtado JM, Winthrop KL, i wsp. Ocular toxoplasmosis II: clinical features, pathology and management. Clin Exp Ophthalmol 2013; 41: 95-108.
 
12.
London NJ, Hovakimyan A, Cubillan LD i wsp. Prevalence, clinical characteristics, and causes of vision loss in patients with ocular toxoplasmosis. Eur J Ophthalmol 2011; 21: 811-819.
 
13.
Vasconcelos-Santos DV. Ocular manifestations of systemic disease: toxoplasmosis. Curr Opin Ophthalmol 2012; 23: 543-550.
 
14.
Azevedo MH, Moura GL, Camilo EN i wsp. Visual function and macular architecture in patients with inactive zone 2 and 3 toxoplasmic retinochoroiditis. Arq Bras Oftalmol 2015; 78: 273-277.
 
15.
Prusa AR, Hayde M, Pollak A i wsp. Evaluation of the liaison automated testing system for diagnosis of congenital toxoplasmosis. Clin Vaccine Immunol 2012; 19: 1859-1863.
 
16.
Lima GS, Saraiva PG, Saraiva FP. Current therapy of acquired ocular toxoplasmosis: a review. J Ocul Pharmacol Ther 2015; 31: 511-517.
 
17.
Neville AJ, Zach SJ, Wang X i wsp. Clinically available medicines demonstrating anti-toxoplasma activity. Antimicrob Agents Chemother 2015; 59: 7161-7169.
 
18.
Glasner PD, Silveira C, Kruszon-Moran D, i wsp. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol 1992: 114: 136-144.
 
19.
Bowie WR, King AS, Werker DH i wsp. Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet 1997; 350: 173-177.
 
20.
de-la-Torre A, Lopez-Castillo CA, Gomez-Marin JE. Incidence and clinical characteristics in a Colombian cohort of ocular toxoplasmosis. Eye (Lond) 2009; 23: 1090-1093.
 
21.
Arantes TE, Silveira C, Holland GN i wsp. Ocular involvement following postnatally acquired Toxoplasma gondii infection in Southern Brazil: A 28-year experience. Am J Ophthalmol 2015; 159: 1002-1012.e2.
 
22.
Garweg JG. Ocular toxoplasmosis: an update. Klin Monbl Augenheilkd 2016; 233: 534-539.
 
23.
Shobab L, Pleyer U, Johnsen J i wsp. Toxoplasma serotype is associated with development of ocular toxoplasmosis. J Infect Dis 2013; 208: 1520-1528.
 
24.
Montazeri M, Sharif M, Sarvi S i wsp. A systematic review of in vitro and in vivo activities of anti-Toxoplasma drugs and compounds (2006-2016). Front Microbiol 2017; 8: 25.
 
25.
Milewska-Bobula B, Lipka B, Gołąb E i wsp. Recommended management of Toxoplasma gondii infection in pregnant women and their children. Przegl Epidemiol 2015; 69: 291-298, 403-410.
 
26.
Jasper S, Vedula SS, John SS i wsp. Corticosteroids as adjuvant therapy for ocular toxoplasmosis. Cochrane Database Syst Rev 2017; 1: CD007417.
 
27.
Souza CE, Nascimento H, Lima A i wsp. Intravitreal injection of sulfamethoxazole and trimethoprim associated with dexamethasone as an alternative therapy for ocular toxoplasmosis. Ocul Immunol Inflamm 2017; 27: 1-4.
 
28.
Aleixo AL, Curi AL, Benchimol EI i wsp. Toxoplasmic retinochoroiditis: clinical characteristics and visual outcome in a prospective study. PLoS Negl Trop Dis 2016; 10: e0004685.
 
29.
Reich M, Ruppenstein M, Becker MD i wsp. Time patterns of recurrences and factors predisposing for a higher risk of recurrence of ocular toxoplasmosis. Retina 2015; 35: 809-819.
 
30.
Pradhan E, Bhandari S, Gilbert RE i wsp. Antibiotics versus no treatment for toxoplasma retinochoroiditis. Cochrane Database Syst Rev 2016; 5: CD002218.
 
31.
Fernandes Felix JP, Cavalcanti Lira RP, Cosimo AB i wsp. Trimethoprim-sulfamethoxazole versus placebo in reducing the risk of toxoplasmic retinochoroiditis recurrences: a three-year follow-up. Am J Ophthalmol 2016; 170: 176-182.
 
32.
Villard O, Cimon B, L’Ollivier C i wsp. Serological diagnosis of Toxoplasma gondii infection: recommendations from the French National Reference Center for toxoplasmosis. Diagn Microbiol Infect Dis 2016; 84: 22-33.
 
33.
de Jesus LN, Tonini Ade C, Barros GB i wsp. IgA and IgG1 reactivities assessed by flow cytometry mirror clinical aspects of infants with ocular congenital toxoplasmosis. J Immunol Methods 2016; 428: 1-8.
 
34.
Roh M, Yasa C, Cho H i wsp. The role of serological titres in the diagnosis of ocular toxoplasmosis. Acta Ophthalmol 2016; 94: 521-522.
 
Journals System - logo
Scroll to top